Daiwa Securities Group Inc. Purchases 535 Shares of Catalent, Inc. (NYSE:CTLT)

Daiwa Securities Group Inc. boosted its position in Catalent, Inc. (NYSE:CTLT) by 2.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,380 shares of the company’s stock after buying an additional 535 shares during the period. Daiwa Securities Group Inc.’s holdings in Catalent were worth $1,096,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Park Place Capital Corp increased its position in Catalent by 25.2% in the 3rd quarter. Park Place Capital Corp now owns 1,533 shares of the company’s stock valued at $70,000 after buying an additional 309 shares in the last quarter. Teacher Retirement System of Texas increased its position in Catalent by 2.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 13,966 shares of the company’s stock valued at $636,000 after buying an additional 350 shares in the last quarter. Arizona State Retirement System increased its position in Catalent by 0.7% in the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock valued at $2,226,000 after buying an additional 365 shares in the last quarter. Treasurer of the State of North Carolina boosted its stake in Catalent by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 81,729 shares of the company’s stock valued at $3,721,000 after purchasing an additional 421 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in Catalent by 5.5% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 8,485 shares of the company’s stock valued at $386,000 after purchasing an additional 446 shares during the last quarter.

Catalent Price Performance

Catalent stock opened at $55.92 on Thursday. Catalent, Inc. has a 12 month low of $31.45 and a 12 month high of $60.20. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The business’s 50 day simple moving average is $56.78 and its 200 day simple moving average is $48.48. The company has a market cap of $10.12 billion, a price-to-earnings ratio of -8.22, a PEG ratio of 6.05 and a beta of 1.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Friday, February 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the company posted $0.62 EPS. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. Sell-side analysts forecast that Catalent, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

CTLT has been the subject of a number of analyst reports. StockNews.com initiated coverage on Catalent in a research note on Friday, April 19th. They set a “sell” rating for the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. UBS Group reiterated a “neutral” rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Stephens reiterated an “equal weight” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Finally, Barclays lifted their price target on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $52.46.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.